<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01029743</url>
  </required_header>
  <id_info>
    <org_study_id>14793</org_study_id>
    <secondary_id>XA0910KR</secondary_id>
    <nct_id>NCT01029743</nct_id>
  </id_info>
  <brief_title>Xarelto Regulatory Post-Marketing Surveillance</brief_title>
  <official_title>XareltoÂ® Regulatory Post-Marketing Surveillance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to identify the following problems and questions with respect to the safety and&#xD;
      effectiveness of Xarelto in comparison with other pharmacologic agents in the prophylaxis of&#xD;
      venous thromboembolism (VTE) in a large sample of patients who undergo elective total hip&#xD;
      replacement (THR) or total knee replacement (TKR) in the real-life conditions in its&#xD;
      registered indication(s) as required by Korean Food and Drug Administration (KFDA).&#xD;
&#xD;
        1. Known and unknown adverse reactions, especially serious adverse reactions&#xD;
&#xD;
        2. Incidence of adverse reactions under the routine drug use&#xD;
&#xD;
        3. Factors that may affect the safety of the drug&#xD;
&#xD;
        4. Factors that may affect the effectiveness of the drug&#xD;
&#xD;
        5. Other safety information related to overuse, drug interaction and laboratory&#xD;
           abnormalities&#xD;
&#xD;
        6. Other adverse reactions&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse event collection</measure>
    <time_frame>From the start of signed consent to 4 weeks after discharge</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of treatment</measure>
    <time_frame>Whole treatment period</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">3388</enrollment>
  <condition>Venous Thromboembolism</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban (Xarelto, BAY59-7939)</intervention_name>
    <description>Daily dose, a treatment duration of 5 weeks for patients undergoing major hip surgery and a treatment duration of 2 weeks for patients undergoing major knee surgery are recommended</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pharmacologic agents (e.g. LMWH/VKA/Fondaparinux/Aspirin and etc.)</intervention_name>
    <description>Daily dose, dosage frequency and duration will be decided by physicians</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who will be treated with rivaroxaban or other pharmacologic agents (e.g.&#xD;
        LMWH/VKA/Fondaparinux) to prevent VTE after elective total hip replacement or total knee&#xD;
        replacement&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female and male patients &gt;/= 18 years of age who will undergo elective total hip&#xD;
             replacement or total knee replacement and receive Xarelto or other pharmacologic&#xD;
             standard of care Venous Thromboembolism (VTE) prophylaxis, and who consent to&#xD;
             participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with hypersensitivity to any pharmacologic VTE prophylaxis treatment&#xD;
&#xD;
          -  Patients with clinically significant active bleeding (e.g., intracranial bleeding,&#xD;
             gastrointestinal bleeding)&#xD;
&#xD;
          -  Patients with significant hepatic disease which is associated with coagulopathy&#xD;
             leading to a clinically relevant bleeding risk&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Patients with hereditary problems of lactose or galactose intolerance (e.g., the Lapp&#xD;
             lactase deficiency or glucose-galactose malabsorption)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>December 9, 2009</study_first_submitted>
  <study_first_submitted_qc>December 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2009</study_first_posted>
  <last_update_submitted>January 19, 2017</last_update_submitted>
  <last_update_submitted_qc>January 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TKR (Total Knee Replacement)</keyword>
  <keyword>THR (Total Hip Replacement)</keyword>
  <keyword>VTE (Venous Thromboembolism)</keyword>
  <keyword>LMWH (Low Molecular Weight Heparin)</keyword>
  <keyword>VKA (Vitamin K antagonist)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>PENTA</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
    <mesh_term>Fondaparinux</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

